

# European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)

Background of Enpr-EMA





#### Legal basis

**Enpr-EMA** 

### **European Paediatric Regulation:**

"The EMA shall, with the scientific support of the Paediatric Committee, develop a European network of existing national and European networks, investigators and centres with specific expertise in the performance of studies in the paediatric population."

**Enpr-EMA** 


# **Objectives/Operational goals of Enpr-EMA**

- > Collaboration and communication (between existing networks and stakeholders)
- Facilitation of recruitment in clinical trials (providing expertise and access to infrastructure for industry to conduct studies in children)
- > Building competences (defining strategies for resolving major challenges)
- > Avoiding unnecessary studies
- Stimulating high quality research (defining consistent and transparent quality standards; harmonising clinical trial procedures)
- Strengthening the foundations of the European Research Area



**Enpr-EMA** 

#### **Organisation and structure**





# **Stakeholders**

**Enpr-EMA** 

- Pharmaceutical Industry
- Patients, parents and patient organisations
- National Competent Authorities
- Ethics Committees
- Medical devices industry
- ≻ CRO's
- ➤ Hospital pharmacists
- Laboratories and imaging centres



# What has been achieved so far?

- Identification of existing networks
- > Implementation strategy adopted by EMA Management Board (Jan 2008)
- > 1<sup>st</sup> workshop with existing networks (Feb 2009)
- ➤ 2 working groups:
  - WG 1: structure and operational model (June 2009)
  - WG 2: definition of recognition criteria (Public consultation Feb 2010)
- $> 2^{nd}$  workshop with existing networks (March 2010)
- > Publication of finalised recognition criteria for self-assessment (May 2010)
- ➤ 3-month period for networks to do self-assessment and publish results.
- > Self-assessment reports screening and clarifications requested (Dec 2010)
- ➤ Publication of list of Networks members of Enpr-EMA (Jan 2011)
- $5 > 3^{rd}$  workshop with existing networks and industry representatives (March 2011)



# **Coordinating Group (background info)**

### **Role of the Coordinating Group:**

**Enpr-EMA** 

- > to contribute to the short and long-term strategy of the network
- > to discuss and solve operational and scientific issues for the network
- ➤ to discuss and agree scientific quality standards
- > to act as a forum for communication

# **Self-assessment report**

**Enpr-EMA** 

Networks should be recognised by quality of paediatric research To elaborate and agree on recognition criteria and quality standards for self-assessment in the following areas:

#### ➤ Capacity

8

- to involve patients (for study design and for recruitment)
- to manage trial and to perform trials according to GCP
- to build up competence and to involve further centres
- to innovate in trials (methodology, techniques, e.g. microassays)
- > Expertise in the therapeutic area
- > Established quality assurance systems of the network
- > Potential conflicts of interest
- > Ability and content to share in relation to competencies and experience

(the elaboration of the self-assessment report was performed using the Delphi and Nominal Group consensus techniques)

### Breakdown of networks by type and category

#### • Table of the current networks and their status:

National	Oncology/ Haematologic Malignancies	Diabetes/ Endocrinology/ metabolic disorders/ Gynaecology	Gastroenterology/ Hepatology	Allergology/ Immunology/ Rheumatology	Stem Cell and Organ Transplantation/ Haematology(non malignant) /Haemostaseology	Respiratory diseases /Cystic Fibrosis
NIHR-MCRN	Newcastle-CLLG	AMIKI	ESPGHAN	PRINTO	EBMT	ECFS-CTN
FinPedMed	ITCC			JSWG of PRES	IPTA	
MCRN-NL	IBFMSG			The second second		
MICYRN	EPOC					
Scotmcn	CLG- of EORTC		-			
CICPed						-
IPCRN	1					

Category 1: Networks fulfilling all minimum criteria for membership of Enpr-EMA.
 Category 2: Networks potentially fulfilling all minimum criteria – but needing to clarify some issues before becoming a member of Enpr-EMA.
 Category 3: Networks currently not yet fulfilling minimum criteria.

							Unable to fill self-
$\frown$				Special Activities / Age Groups			assessment report
Cardiovascular diseases/ Nephrology	Psychiatry/ Neurology	Infectious diseases/ Vaccinology	Intensive Care/Pain/ Anaesthesiology/ Surgery	European neonatal network	European paediatric pharmacists	special activities (Phv, long term follow up, community paediatritians)	Expertise in clinical trial methodology
	EUNETHYDIS	PENTA		GNN		FIMP-MCRN	TEDDY
		UKPVG		EuroNeoNet			PRIOMEDCHILD
		PENTI		Neo-circulation			ECRIN
				INN			GRIP

NCCHD

BLF

RIPPS

Futurenest CR BPDN

10

# Enpr-EMA information: http://www.ema.europa.eu



11

# Enpr-EMA information: http://www.ema.europa.eu

	ean medicines agency	An	Agency of the Euro	pean Unio	
SCIENCE N	MEDICINES HEALTH Text size:	A A Site-wi	A Site-wide search		
Home Find medicine	Regulatory   Special topics   Document search   News & events   Partners & network	s About us	Quick links	0	
Europe & the Agency	▶ Home ▶ Partners & Networks ▶ Networks ▶ Enpr-EMA				
Regulators outside	European Network of Paediatric Research at the				
the EU	European Medicines Agency	🖂 Email 🔓	Print 🔞 Help 🛛	📀 Share	
Patients and consumers	The European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) is a network of research networks, investigators and centres with recognised expertise in performing clinical studies in children.		Related information <ul> <li>Medicines for children</li> </ul>		
Healthcare professionals	Enpr-EMA aims to foster <b>high-quality ethical research</b> on quality, safety and efficacy of medicines to be used in children. It does this through networking and stakeholder		<ul> <li>Paediatric Committee</li> <li>Paediatric medicine development</li> </ul>		
Pharmaceutical industry	collaboration with members from within and outside the European Union (EU). Enpr-EMA's main objectives are to:	尨 The r Netw	The network of Paediatric Networks at the EMEA implementing strategy		
International organisations	<ul> <li>foster high-quality, ethical research on medicines for use in children;</li> <li>enable collaboration between networks and and stakeholders;</li> </ul>	(15/			
Networks	<ul> <li>co-ordinate studies relating to paediatric medicines and avoid unnecessary testing in children;</li> </ul>		point: @ema.europa.eu	J	
ENCEDU Enpr-EMA	<ul> <li>build up scientific and administrative competence at a European level;</li> <li>help with the recruitment of patients for clinical trials;</li> </ul>				
Enpr-EMA membership	promote European Commission framework programme applications.				
ETPGAH	Enpr-EMA does not perform clinical trials or fund studies or research or decide on areas for paediatric research, as this is the responsibility of Member States, the European				
Health technology	Commission or each individual network.				

### Enpr-EMA information: http://www.ema.europa.eu

